Get access
Advertisement

Recent agents targeting HIF-1α for cancer therapy

Authors

  • Yaozhong Hu,

    1. Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
    2. Key Laboratory of System Bioengineering, Ministry of Education, Tianjin University, Tianjin 300072, China
    Search for more papers by this author
  • Jing Liu,

    1. Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
    2. Key Laboratory of System Bioengineering, Ministry of Education, Tianjin University, Tianjin 300072, China
    Search for more papers by this author
  • He Huang

    Corresponding author
    1. Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
    2. Key Laboratory of System Bioengineering, Ministry of Education, Tianjin University, Tianjin 300072, China
    • Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
    Search for more papers by this author

Abstract

The discovery of hypoxia-inducible factor-1 (HIF-1) has led to an increasing understanding of the mechanism of tumor hypoxia in the past two decades. As a key transcriptional regulator, HIF-1 plays a central role in the adaptation of tumor cells to hypoxia by activating the transcription of targeting genes, which regulate several biological processes including angiogenesis, cell proliferation, survival, glucose metabolism and migration. The inhibitors of HIF-1 in cancer have provided us a new clue for the targeting cancer therapy. This review will introduce the general knowledge of the biology characteristic of HIF-1 and mechanism of O2-dependent regulation. Moreover, a number of chemical inhibitors plus protein and nucleic acid inhibitors are included and classified mainly based on their different mechanism of inhibiting action. We also prefer to discuss the advantages of protein and nucleic acid inhibitors compared with chemical inhibitors. J. Cell. Biochem. 114: 498–509, 2013. © 2012 Wiley Periodicals, Inc.

Get access to the full text of this article

Ancillary